Role of vasopressin in essential hypertension: Racial differences

Journal of Hypertension

Volumn 15, Issue 5, 1997, Pages 545-550

  Bakris, George ^a,b,d   Bursztyn, Michael ^c   Gavras, Irene ^c   Bresnahan, Margaret ^c   Gavras, Haralambos ^c  

^a OCHSNER MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

African Americans; Antagonist; Hypertension; Vasopressin

Indexed keywords

ARGIPRESSIN; CLONIDINE; RENIN; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAUCASIAN; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NEGRO; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PRIORITY JOURNAL; RACE DIFFERENCE; RECEPTOR BLOCKING; VASOPRESSIN BLOOD LEVEL; VERTIGO;

EID: 0031011283     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715050-00011     Document Type: Article

References (31)

1. Cowley AW Jr, Cushman WC, Quillen EW Jr, Skelton MM, Langford HG: Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension 1981, 3 (suppl I):I93-I100.
2. Ellis ME, Groliman A: The antidiuretic hormone in the urine in experimental and clinical hypertension. Endocrinology 1949, 44:415-419.
3. Bursztyn M, Bresnahan M, Gavras I, Gavras H: Effect of aging on vasopressin, catecholamines, and alpha2-adrenergic receptors. J Am Geriatr Soc 1990, 38:628-632.
4. Os I, Kjeldsen SE, Skjoto I, Westheim A, Lande K, Aakesson I, et al.: Increased plasma vasopressin in low renin essential hypertension. Hypertension 1986, 8:506-513.
5. Pedersen EB, Danielsen H, Madsen M, Sorensen SS, Thomson OO: Abnormal vasopressin and aldosterone response to furosemide in essential hypertension. Acta Med Scand 1986, 219:387-392.
6. Ribeiro A, Mulinari R, Gavras I, Kohlmann O, Ramos O, Gavras H: Sequential elimination of pressor mechanisms in severe hypertension in humans. Hypertension 1986, 8 (suppl 1):I169-I173.
7. Gavras H, Ribeiro AB, Kohlmann O, Saragoca M, Mulinari RA, Ramos O, et al.: Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension 1984, 6 (suppl 1):I156-I160.
8. Bursztyn M, Bresnahan M, Gavras I, Gavras H: Pressor hormones in elderly hypertensive persons - racial differences. Hypertension 1990, 15 (suppl 1):I88-I92.
9. Cowley AW, Skelton MM, Velasquez MT: Sex differences in the endocrine predictors of essential hypertension - vasopressin versus renin. Hypertension 1985, 7 (suppl 1):I151-I160.
10. Thibonnier M: Vasopressin in blood pressure. Kidney Int 1988, 34 (suppl 25):S5-S56.
11. Jard S: Vasopressin antagonists. Adv Nephrol 1987, 16:1-16.
12. La Rochelle FT, North WG, Stern P: A new extraction of arginine vasopressin from blood: the use of octadecasilyl-silica. Pflügers Arch 1980, 387:79-81.
13. Davis GC, Kissinger PT, Sharp RE: Strategies for determination of serum or plasma norepinephrine by reverse phase liquid chromatography. Anal Chem 1981, 53:156-159.
14. Sealey JE, Gerten Banes J, Laragh JH: The renin system variation in man measured by radioimmunoassay or bioassay. Kidney Int 1972, 1:240-253.
15. Falkner B: Differences in African-Americans and whites with essential hypertension: biochemistry and endocrine. Hypertension 1990, 15:681-686.
16. Crofton JT, Dustan H, Share L, Brooks DP: Vasopressin secretion in normotensive African-American and white men and women on normal and low salt diets. J Endocrinol 1986, 108:191-199.
17. Gavras H, Hatzinikolaou P, North WG, Bresnahan M, Gavras I: Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension 1982, 4:400-405.
18. Gavras I, Hatinoglou S, Gavras H: The adrenergic system and the release and pressor action of vasopressin. Hypertension 1986, 8 (suppl 11):II163-II167.
19. Hollister AS, Onrot J, Lance S, Nadeau JHJ, Robertson D: Plasma catechotamine modulation of alpha-2-adrenoceptor agonist affinity and sensitivity in normotensive and hypertensive human platelets. J Clin Invest 1986, 77:1416-1421.
20. Reid LA, Nolan PL, Wolf JA, Keil LC: Suppression of vasopressin secretion by clonidine: effects of alpha adrenoceptor antagonists. Endocrinology 1979, 104:1403-1406.
21. Chabardes D, Montegut M, Imbert Teboul M, Morel F: Inhibition of alpha2-adrenergic agonists on AVP-induced cAMP accumulation in isolated collecting tubules of the rat kidney. Mol Cell Endocrinol 1984, 37:263-275.
22. Fisher DA: NE inhibition of vasopressin antidiuresis. J Clin Invest 1968, 47:540-547.
23. Pettinger WA, Umemura S, Smyth DD, Jeffries WB: Renal alpha2-adrenoceptors and the adenylate cyclase-cAMP system: biochemical and physiological interactions. Am J Physiol 1987, 252:F199-F208.
24. Sklar AH, Schrier RW: Central nervous system mediators of vasopressin release. Physiol Rev 1983, 63:1243-1280.
25. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I: Sodium-induced elevation of blood pressure in the anephric state. Science 1980, 209:935-938.
26. DiPette DJ, Gavras I, North WG, Brunner HR, Gavras H: Vasopressin in salt-induced hypertension of experimental renal insufficiency. Hypertension 1982, 4 (suppl 11):II125-II131.
27. Papadoliopoulou-Diamandopoulou N, Papagalanis N, Gavras I, Gavras H: Vasopressin in end stage renal disease: relationship to salt, catecholamines and renin activity. Clin Exp Theor Pract [A] 1987, 9:1197-1208.
28. De Paula RB, Plavnic FL, Rodrigues CIS, De la Rocha Neves F, Kohlmann O, Ribeiro AB, et al.: Age and race determine vasopressin participation in upright blood pressure control in essential hypertension. Ann NY Acad Sci 1993, 689:534-536
29. Berecek KH: Role of central vasopressin in cardiovascular regulation. J Cardiovasc Pharmacol 1986, 8 (suppl 7):76-80.
30. Gavras H, Gavras I: Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. J Hypertens 1989, 4:601-606.
31. Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, et al., OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991, 252:572-574.